Table 3

Histological characteristics of 25 patients with liver-related irAEs

Histological parametersHepatitic (n=14)Cholangio-hepatitic (n=6)Cholangitic (n=4)
Lobular inflammation
02 (14%)1 (17%)0 (0%)
13 (21%)5 (83%)4 (100%)
27 (50%)0 (0%)0 (0%)
32 (14%)0 (0%)0 (0%)
Lobular necrosis
02 (14%)2 (33%)0 (0%)
16 (43%)4 (67%)4 (100%)
26 (43%)0 (0%)0 (0%)
30 (0%)0 (0%)0 (0%)
Centrilobular injury
06 (43%)5 (83%)4 (100%)
15 (36%)1 (17%)0 (0%)
22 (14%)0 (0%)0 (0%)
31 (7%)0 (0%)0 (0%)
Portal inflammation
00 (0%)0 (0%)0 (0%)
17 (50%)1 (17%)1 (25%)
24 (29%)4 (66%)2 (50%)
33 (21%)1 (17%)1 (25%)
Interface hepatitis
04 (29%)2 (33%)0 (0%)
16 (43%)2 (33%)4 (100%)
21 (7%)2 (33%)0 (0%)
33 (21%)0 (0%)0 (0%)
Specific cell subpopulations
Plasma cells
05 (36%)2 (33%)1 (25%)
18 (57%)4 (66%)3 (75%)
21 (7%)0 (0%)0 (0%)
30 (0%)0 (0%)0 (0%)
Eosinophils
05 (36%)1 (17%)1 (25%)
14 (29%)4 (66%)2 (50%)
25 (36%)1 (17%)1 (25%)
Neutrophils
03 (21%)0 (0%)0 (0%)
19 (64%)2 (33%)1 (25%)
22 (14%)4 (67%)3 (75%)
Biliary abnormalities
Bile duct injury
08 (57%)0 (0%)0 (0%)
16 (43%)6 (100%)4 (100%)
Ductular reaction
03 (21%)0 (0%)0 (0%)
18 (57%)0 (0%)0 (0%)
23 (21%)5 (83%)3 (75%)
30 (0%)1 (17%)1 (25%)
Biliary metaplasia
011 (79%)1 (17%)2 (50%)
13 (21%)3 (50%)0 (0%)
20 (0%)1 (17%)1 (25%)
30 (0%)1 (17%)1 (25%)
Granulomas
04 (29%)6 (100%)1 (25%)
17 (50%)0 (0%)3 (75%)
23 (21%)0 (0%)0 (0%)
Fibrosis
F04 (29%)0 (0%)0 (0%)
F19 (64%)3 (50%)3 (75%)
F21 (7%)2 (33%)0 (0%)
F2/F30 (0%)1 (17%)1 (25%)
CD4+/CD8+ ratio1264
≤110 (83%)4 (66%)2 (50%)
>12 (17%)2 (33%)2 (50%)
  • One patient had only macrovesicular steatosis at the biopsy and could not be included in either of the immune-related hepatitis, cholangitis or cholangiohepatitis classes. Classification is based on the description of histological features in online supplemental table 4.

  • irAEs, immune-related adverse events.